Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03474107




Registration number
NCT03474107
Ethics application status
Date submitted
16/03/2018
Date registered
22/03/2018
Date last updated
16/10/2024

Titles & IDs
Public title
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Scientific title
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Secondary ID [1] 0 0
2017-003344-21
Secondary ID [2] 0 0
7465-CL-0301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ureteral Cancer 0 0
Urothelial Cancer 0 0
Bladder Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Enfortumab Vedotin
Treatment: Drugs - Docetaxel
Treatment: Drugs - Vinflunine
Treatment: Drugs - Paclitaxel

Experimental: Arm A: Enfortumab Vedotin 1.25 mg/kg - Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.

Active comparator: Arm B: Chemotherapy - Participants received either 75 milligrams per square meter (mg/m\^2) docetaxel by IV infusion over approximately 1 hour or 320 mg/m\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\^2 paclitaxel by IV infusion over approximately 1 hour on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.

Experimental: Cross-over Extension (COE) - Eligible participants from chemotherapy arm who met the criteria for COE will receive 1.25 mg/kg of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle until discontinuation criteria is met.


Treatment: Drugs: Enfortumab Vedotin
Intravenous infusion

Treatment: Drugs: Docetaxel
Intravenous infusion

Treatment: Drugs: Vinflunine
Intravenous infusion

Treatment: Drugs: Paclitaxel
Intravenous infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)
Secondary outcome [1] 0 0
Progression Free Survival on Study Therapy (PFS1) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Timepoint [1] 0 0
From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)
Secondary outcome [2] 0 0
Overall Response Rate (ORR) as Per RECIST V1.1
Timepoint [2] 0 0
From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)
Secondary outcome [3] 0 0
Disease Control Rate (DCR) as Per RECIST V1.1
Timepoint [3] 0 0
From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)
Secondary outcome [4] 0 0
Duration of Response (DOR) as Per RECIST V1.1
Timepoint [4] 0 0
From date of first objective response until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)
Secondary outcome [5] 0 0
Change From Baseline to Week 12 in European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Global Health Status (QL2 Score)
Timepoint [5] 0 0
Baseline and week 12
Secondary outcome [6] 0 0
Change From Baseline to Week 12 in EuroQOL 5-dimension 5-level Questionnaire [EQ-5D-5L] Visual Analog Scale (VAS)
Timepoint [6] 0 0
Baseline and week 12
Secondary outcome [7] 0 0
Number of Participants With Treatment Emergent Adverse Events
Timepoint [7] 0 0
From first dose up to 30 days after last dose (Median (range) time on study drug was 4.99 (0.5, 19.4) months in enfortumab vedotin and 3.45 (0.2, 15.0) months in chemotherapy group)
Secondary outcome [8] 0 0
Number of Participants With ECOG Performance Status
Timepoint [8] 0 0
End of treatment (EOT) (Median (range) time on study drug was 4.99 (0.5, 19.4) months in enfortumab vedotin and 3.45 (0.2, 15.0) months in chemotherapy group)

Eligibility
Key inclusion criteria
* Subject is legally an adult according to local regulation at the time of signing informed consent.
* Subject has histologically or cytologically confirmed urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Subjects with urothelial carcinoma (transitional cell) with squamous differentiation or mixed cell types are eligible.
* Subject must have experienced radiographic progression or relapse during or after a checkpoint inhibitor (CPI) (anti-programmed cell death protein 1 (PD1) or anti-programmed death-ligand 1 (PD-L1)) for locally advanced or metastatic disease. Subjects who discontinued CPI treatment due to toxicity are eligible provided that the subjects have evidence of disease progression following discontinuation. The CPI need not be the most recent therapy. Subjects for whom the most recent therapy has been a non-CPI based regimen are eligible if the subjects have progressed/relapsed during or after the subjects most recent therapy. Locally advanced disease must not be amenable to resection with curative intent per the treating physician.
* Subject must have received a platinum containing regimen (cisplatin or carboplatin) in the metastatic/locally advanced, neoadjuvant or adjuvant setting. If platinum was administered in the adjuvant/neoadjuvant setting subject must have progressed within 12 months of completion.
* Subject has radiologically documented metastatic or locally advanced disease at baseline.
* An archival tumor tissue sample should be available for submission to central laboratory prior to study treatment. If an archival tumor tissue sample is not available, a fresh tissue sample should be provided. If a fresh tissue sample cannot be provided due to safety concerns, enrollment into the study must be discussed with the medical monitor.
* Subject has ECOG PS of 0 or 1
* The subject has the following baseline laboratory data:

* absolute neutrophil count (ANC) = 1500/mm3
* platelet count = 100 × 10^9/L
* hemoglobin = 9 g/dL
* serum total bilirubin = 1.5 × upper limit of normal (ULN) or = 3 × ULN for subjects with Gilbert's disease
* creatinine clearance (CrCl) = 30 mL/min as estimated per institutional standards or as measured by 24 hour urine collection (glomerular filtration rate [GFR] can also be used instead of CrCl)
* alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × ULN or = 3 x ULN for subjects with liver metastases
* Female subject must either:

* Be of nonchildbearing potential: Postmenopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
* Or, if of childbearing potential: Agree not to try to become pregnant during the study and for at least 6 months after the final study drug administration, and have a negative urine or serum pregnancy test within 7 days prior to Day 1 (Females with false positive results and documented verification of negative pregnancy status are eligible for participation), and if heterosexually active, agree to consistently use a condom plus 1 form of highly effective birth control per locally accepted standards starting at screening and throughout the study period and for at least 6 months after the final study drug administration.
* Female subject must agree not to breastfeed or donate ova starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.
* A sexually active male subject with female partner(s) who is of childbearing potential is eligible if:

* Agrees to use a male condom starting at screening and continue throughout the study treatment and for at least 6 months after final study drug administration. If the male subject has not had a vasectomy or is not sterile as defined below the subjects female partner(s) is utilizing 1 form of highly effective birth control per locally accepted standards starting at screening and continue throughout study treatment and for at least 6 months after the male subject receives final study drug administration.
* Male subject must not donate sperm starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.
* Male subject with a pregnant or breastfeeding partner(s) must agree to abstinence or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for at least 6 months after the final study drug administration.
* Subject agrees not to participate in another interventional study while on treatment in present study.

Inclusion Criteria for COE:

* Subject is eligible for the COE if they continue to meet all inclusion criteria from the main protocol in addition to the following when the patient is evaluated for eligibility to participate in the COE portion of the study:
* Institutional review board (IRB)/ independent ethics committee (IEC) approved written COE informed consent and privacy language as per national regulations (e.g., health insurance portability and accountability act [HIPAA] Authorization for US sites) must be obtained from the subject prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
* Subject was randomized to Arm B and is either currently on study treatment or has discontinued study treatment due to intolerance, AE or progression of disease and has not started a new systemic anticancer treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject has preexisting sensory or motor neuropathy Grade = 2.
* Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:

* CNS metastases have been clinically stable for at least 6 weeks prior to screening
* If requiring steroid treatment for CNS metastases, the subject is on a stable dose = 20 mg/day of prednisone or equivalent for at least 2 weeks
* Baseline scans show no evidence of new or enlarged brain metastasis
* Subject does not have leptomeningeal disease
* Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery). Subject with = Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well-maintained/controlled on a stable dose of hormone replacement therapy (if indicated). Subjects with ongoing = Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy related colitis, uveitis, or pneumonitis or subjects with other immunotherapy related AEs requiring high doses of steroids (> 20 mg/day of prednisone or equivalent) are excluded.
* Subject has prior treatment with EV or other monomethyl auristatin E (MMAE)-based Antibody drug conjugates (ADCs).
* Subject has received prior chemotherapy for urothelial cancer with all available study therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is an approved therapy).
* Subject has received more than 1 prior chemotherapy regimen for locally advanced or metastatic urothelial cancer, including chemotherapy for adjuvant or neo-adjuvant disease if recurrence occurred within 12 months of completing therapy. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen.
* Subject has history of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with nonmelanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
* Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of EV. Routine antimicrobial prophylaxis is permitted.
* Subject has known active Hepatitis B (e.g., hepatitis B surface antigen (HBsAg) reactive) or active hepatitis C (e.g., hepatitis C virus (HCV) Ribonucleic Acid (RNA) [qualitative] is detected).
* Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).
* Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.
* Subject has radiotherapy or major surgery within 4 weeks prior to first dose of study drug.
* Subject has had chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.
* Subject has known hypersensitivity to EV or to any excipient contained in the drug formulation of EV; OR subject has known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary (CHO) cells.
* Subject has known hypersensitivity to the following: docetaxel or to any of the other excipients listed in product label, including polysorbate 80, paclitaxel or to any of the other excipients listed in product label, such as macrogolglycerol ricinoleate 35 (Ph.Eur.); and vinflunine or to any of the other excipients listed in product label such as other vinca alkaloids (vinblastine,vincristine, vindesine, vinorelbine).
* Subject has known active keratitis or corneal ulcerations.
* Subject has other underlying medical condition that would impair the ability of the subject to receive or tolerate the planned treatment and follow-up.
* History of uncontrolled diabetes mellitus within 3 months of the first dose of study drug. Uncontrolled diabetes is defined as hemoglobin A1C (HbA1c) = 8% or HbA1c between 7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.

Exclusion Criteria for COE

* Subject will be excluded from participation in the COE if they meet any of the exclusion criteria listed in the main protocol or if any of the following apply when the patient is evaluated for eligibility to participate in the COE portion of the study:
* Subject has been diagnosed with a new malignancy while on Arm B in the EV-301 study. Subjects with nonmelanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
* Subject has already started commercial EV or arrangements have been made for subject to start commercial EV which is reimbursed in their country. Additionally, if EV is commercially available with reimbursement in the potential subject's country, the subject can consider transitioning to the commercial product unless otherwise discussed with sponsor.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/06/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/02/2025
Actual
Sample size
Target
Accrual to date
Final
608
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Site AU61006 - Adelaide
Recruitment hospital [2] 0 0
Site AU61001 - Miranda
Recruitment hospital [3] 0 0
Site AU61004 - St. Leonards
Recruitment hospital [4] 0 0
Site AU61002 - Sydney
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Miranda
Recruitment postcode(s) [3] 0 0
- St. Leonards
Recruitment postcode(s) [4] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Rhode Island
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Austria
State/province [19] 0 0
Linz
Country [20] 0 0
Austria
State/province [20] 0 0
Salzburg
Country [21] 0 0
Austria
State/province [21] 0 0
Wien
Country [22] 0 0
Belgium
State/province [22] 0 0
Aalst
Country [23] 0 0
Belgium
State/province [23] 0 0
Brussels
Country [24] 0 0
Belgium
State/province [24] 0 0
Charleroi
Country [25] 0 0
Belgium
State/province [25] 0 0
Gent
Country [26] 0 0
Belgium
State/province [26] 0 0
Hasselt
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Belgium
State/province [28] 0 0
Liège
Country [29] 0 0
Canada
State/province [29] 0 0
Calgary
Country [30] 0 0
Canada
State/province [30] 0 0
Edmonton
Country [31] 0 0
Canada
State/province [31] 0 0
London
Country [32] 0 0
Canada
State/province [32] 0 0
Montreal
Country [33] 0 0
Canada
State/province [33] 0 0
Oshawa
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
Canada
State/province [35] 0 0
Saskatoon
Country [36] 0 0
Canada
State/province [36] 0 0
Sherbrooke
Country [37] 0 0
Canada
State/province [37] 0 0
Toronto
Country [38] 0 0
Canada
State/province [38] 0 0
Vancouver
Country [39] 0 0
Denmark
State/province [39] 0 0
Aalborg
Country [40] 0 0
Denmark
State/province [40] 0 0
Copenhagen
Country [41] 0 0
Denmark
State/province [41] 0 0
Herlev
Country [42] 0 0
France
State/province [42] 0 0
Besancon
Country [43] 0 0
France
State/province [43] 0 0
Bordeaux
Country [44] 0 0
France
State/province [44] 0 0
Brest
Country [45] 0 0
France
State/province [45] 0 0
Caen
Country [46] 0 0
France
State/province [46] 0 0
Lyon
Country [47] 0 0
France
State/province [47] 0 0
Marseille
Country [48] 0 0
France
State/province [48] 0 0
Nice
Country [49] 0 0
France
State/province [49] 0 0
Paris
Country [50] 0 0
France
State/province [50] 0 0
Pierre-Bénite
Country [51] 0 0
France
State/province [51] 0 0
Saint-Mande
Country [52] 0 0
France
State/province [52] 0 0
Strasbourg
Country [53] 0 0
France
State/province [53] 0 0
Toulouse
Country [54] 0 0
France
State/province [54] 0 0
Villejuif
Country [55] 0 0
Germany
State/province [55] 0 0
Essen
Country [56] 0 0
Germany
State/province [56] 0 0
Heidelberg
Country [57] 0 0
Germany
State/province [57] 0 0
Münster
Country [58] 0 0
Germany
State/province [58] 0 0
Tübingen
Country [59] 0 0
Germany
State/province [59] 0 0
Würzburg
Country [60] 0 0
Italy
State/province [60] 0 0
Arezzo
Country [61] 0 0
Italy
State/province [61] 0 0
Cremona
Country [62] 0 0
Italy
State/province [62] 0 0
Milan
Country [63] 0 0
Italy
State/province [63] 0 0
Modena
Country [64] 0 0
Italy
State/province [64] 0 0
Pisa
Country [65] 0 0
Italy
State/province [65] 0 0
Reggio Emilia
Country [66] 0 0
Italy
State/province [66] 0 0
Terni
Country [67] 0 0
Japan
State/province [67] 0 0
Aomori
Country [68] 0 0
Japan
State/province [68] 0 0
Chiba
Country [69] 0 0
Japan
State/province [69] 0 0
Hokkaido
Country [70] 0 0
Japan
State/province [70] 0 0
Ibaraki
Country [71] 0 0
Japan
State/province [71] 0 0
Iwate
Country [72] 0 0
Japan
State/province [72] 0 0
Kagawa
Country [73] 0 0
Japan
State/province [73] 0 0
Kanagawa
Country [74] 0 0
Japan
State/province [74] 0 0
Miyagi
Country [75] 0 0
Japan
State/province [75] 0 0
Osaka
Country [76] 0 0
Japan
State/province [76] 0 0
Tokyo
Country [77] 0 0
Japan
State/province [77] 0 0
Yamaguchi
Country [78] 0 0
Japan
State/province [78] 0 0
Fukuoka
Country [79] 0 0
Japan
State/province [79] 0 0
Hiroshima
Country [80] 0 0
Japan
State/province [80] 0 0
Kyoto
Country [81] 0 0
Japan
State/province [81] 0 0
Niigata
Country [82] 0 0
Japan
State/province [82] 0 0
Okayama
Country [83] 0 0
Japan
State/province [83] 0 0
Tokushima
Country [84] 0 0
Japan
State/province [84] 0 0
Toyama
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Daejeon
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Goyang-Si
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Hwasun-gun
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Incheon
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Seongnam-si
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Seoul
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Shin
Country [92] 0 0
Netherlands
State/province [92] 0 0
Amsterdam
Country [93] 0 0
Netherlands
State/province [93] 0 0
Nijmegen
Country [94] 0 0
Netherlands
State/province [94] 0 0
Tilburg
Country [95] 0 0
Portugal
State/province [95] 0 0
Lisboa
Country [96] 0 0
Portugal
State/province [96] 0 0
Lisbon
Country [97] 0 0
Portugal
State/province [97] 0 0
Porto
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Ivanovo
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Obninsk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Omsk
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Vologda
Country [102] 0 0
Spain
State/province [102] 0 0
Badajoz
Country [103] 0 0
Spain
State/province [103] 0 0
Badalona
Country [104] 0 0
Spain
State/province [104] 0 0
Barcelona
Country [105] 0 0
Spain
State/province [105] 0 0
Córdoba
Country [106] 0 0
Spain
State/province [106] 0 0
Madrid
Country [107] 0 0
Spain
State/province [107] 0 0
Manresa
Country [108] 0 0
Spain
State/province [108] 0 0
Pamplona
Country [109] 0 0
Spain
State/province [109] 0 0
Seville
Country [110] 0 0
Spain
State/province [110] 0 0
Valencia
Country [111] 0 0
Switzerland
State/province [111] 0 0
Bern
Country [112] 0 0
Switzerland
State/province [112] 0 0
Chur
Country [113] 0 0
Taiwan
State/province [113] 0 0
Kaohsiung
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taichung
Country [115] 0 0
Taiwan
State/province [115] 0 0
Tainan
Country [116] 0 0
Taiwan
State/province [116] 0 0
Taipei
Country [117] 0 0
Taiwan
State/province [117] 0 0
Taoyuan
Country [118] 0 0
United Kingdom
State/province [118] 0 0
London
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Sheffield
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Southampton
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Sutton
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Wirral

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Astellas Pharma Global Development, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Seagen Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.

This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy.

In addition, this study evaluated the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assessed the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.
Trial website
https://clinicaltrials.gov/study/NCT03474107
Trial related presentations / publications
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Astellas Pharma Global Development, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03474107